



## **Nkarta to Participate in September Investor Conferences**

September 10, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:

### **September 16, 2026**

H.C. Wainwright 28th Annual Global Investment Conference  
New York, NY  
10:30 a.m. ET – fireside chat

### **September 23, 2026**

Stifel 2026 Virtual Immunology and Inflammation Forum  
12:30 p.m. ET – fireside chat

A simultaneous webcast of both events will be available on the [Investors section](#) of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately 90 days.

### **About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

### **Nkarta Media/Investor Contact:**

Nadir Mahmood  
Nkarta, Inc.  
[nmahmood@nkartatx.com](mailto:nmahmood@nkartatx.com)